• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve.

作者信息

Galiuto Leonarda, Patrono Carlo

机构信息

Assistant Professor of Cardiology, Fondazione Policlinico A. Gemelli-IRCSS, Catholic University of the Sacred Heart Rome, Italy.

Adjunct Professor of Pharmacology, Catholic University, School of Medicine, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

出版信息

Eur Heart J. 2021 Feb 21;42(8):811-812. doi: 10.1093/eurheartj/ehaa1075.

DOI:10.1093/eurheartj/ehaa1075
PMID:33398340
Abstract
摘要

相似文献

1
Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve.利伐沙班，心房颤动合并生物瓣二尖瓣置换术后患者的一种新选择。
Eur Heart J. 2021 Feb 21;42(8):811-812. doi: 10.1093/eurheartj/ehaa1075.
2
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):973-974. doi: 10.1056/NEJMc2035891.
3
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):975. doi: 10.1056/NEJMc2035891.
4
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):974-975. doi: 10.1056/NEJMc2035891.
5
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者
N Engl J Med. 2021 Mar 11;384(10):974. doi: 10.1056/NEJMc2035891.
6
In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.在合并有房颤和生物瓣二尖瓣置换的患者中，利伐沙班用于临床事件时间的非劣效于华法林。
Ann Intern Med. 2021 Apr;174(4):JC43. doi: 10.7326/ACPJ202104200-043. Epub 2021 Apr 6.
7
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. Reply.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者。回复
N Engl J Med. 2021 Mar 11;384(10):975-976. doi: 10.1056/NEJMc2035891.
8
Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? - New insights from RIVER trial.房颤合并生物瓣二尖瓣置换术后患者华法林的时代是否即将终结？——RIVER 试验的新见解。
Indian Heart J. 2021 Jul-Aug;73(4):516-517. doi: 10.1016/j.ihj.2021.06.019. Epub 2021 Jul 1.
9
Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.对于接受生物瓣二尖瓣置换术且合并房颤的患者，无需进行口服抗凝治疗。
Z Kardiol. 1986;75 Suppl 2:321-5.
10
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.利伐沙班预防非瓣膜性心房颤动患者的卒中和全身性栓塞：ROCKET AF试验及其亚组分析的临床意义
Am J Cardiovasc Drugs. 2015 Dec;15(6):395-401. doi: 10.1007/s40256-015-0127-2.